Indoco Remedies Limited has made the audio recording of its earnings conference call available to investors and stakeholders. The call addressed the company’s unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This disclosure ensures transparency and provides market participants with direct access to management’s commentary on the latest financial performance.

The earnings conference call was held on July 28, 2026, starting at 3:30 p.m. (IST) and concluding at 4:30 p.m. (IST). Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the company notified the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited regarding the availability of the recording.

Call Details

The audio recording is hosted on the company’s website at https://www.indoco.com/inv-fin-concall-transcripts.asp . Investors can access the full transcript and recording to review management’s discussion on operational highlights, financial metrics, and future outlook for the period.

Corporate Governance

Ramanathan Hariharan, Company Secretary & Head-Legal, signed the disclosure letter on behalf of Indoco Remedies Limited. The notification was digitally signed and timestamped on July 28, 2026, at 16:44:53 IST. The company requested the stock exchanges to take the availability of the recording on record, ensuring compliance with mandatory disclosure norms.

What the Numbers Show

While the specific financial figures were not detailed in this particular filing, the release of the earnings call recording indicates the completion of the Q4FY26 reporting cycle. Market participants are advised to listen to the recording for insights into revenue trends, margin dynamics, and strategic initiatives discussed by the executive team during the session.

The Board of Indoco Remedies approved the re-appointment of Ms. Aditi Panandikar as Managing Director for a five-year term, ensuring leadership continuity for the pharmaceutical firm. The tenure is scheduled to commence on February 15, 2027, and conclude on February 14, 2032, pending final approval from shareholders at the company’s 79th Annual General Meeting. This decision follows recommendations from the Nomination and Remuneration Committee and was ratified during a board meeting held on July 28, 2026.

In a concurrent move to strengthen its senior management structure, the Board also appointed Mr. Sudhir Kadam as Senior Management Personnel, designated as Senior Vice President (Human Capital). His appointment took effect immediately on July 28, 2026, marking a strategic addition to the executive team responsible for human resources and organizational development.

Key Appointments

Ms. Panandikar, who holds a Master’s Degree in Pharmaceutical Administration from Ohio State University, brings over 30 years of experience in domestic marketing, human resources, technical functions including R&D and QA, and business development. As the daughter of Mr. Suresh G Kare, the Company’s Chairman, she has been integral to the organization’s techno-commercial strategy. The filing confirms that she is not debarred from holding office by SEBI or any other authority.

Mr. Kadam joins with a robust background in human resource management, holding a Master’s Degree in Management Studies (Human Resources) from Sydenham Institute of Management Studies and Research, Mumbai University. With three decades of experience across pharma, automotive, farm equipment, and engineering sectors, he will oversee strategic HR, talent management, and leadership development initiatives.

Regulatory Compliance

The announcements were made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part-A of Schedule III. The disclosures align with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The Board meeting commenced at 10:45 a.m. and concluded at 11:45 a.m. on July 28, 2026.

Leadership Continuity

The re-appointment of Ms. Panandikar underscores the Board’s confidence in her long-standing leadership, which has spanned multiple critical functions within the company. Her dual expertise in pharmaceutical administration and commercial operations positions her to navigate the evolving regulatory and market landscapes in the healthcare sector. The simultaneous appointment of Mr. Kadam signals a focus on strengthening internal capabilities, particularly in talent acquisition and retention, which are vital for sustaining growth in a competitive industry. Shareholders will have the opportunity to vote on Ms. Panandikar’s re-appointment at the upcoming annual general meeting.